Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for RET fusion-positive non-small-cell lung cancer, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Solvent-front resistance mutations have no approved inhibitor.
Nothing recorded yet.
Nothing recorded yet.
Background: Oligoprogression, On-target resistance mutations (gatekeeper, solvent-front, compound). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Whether adjuvant selpercatinib prevents recurrence is not yet known.
RNA-based testing is needed to find all fusions but is not universally available.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Objective response 64 percent after platinum chemotherapy and 85 percent in previously untreated RET fusion-positive non-small-cell lung cancer; intracranial response 91 percent.
PFS HR 0.
A milestone in how this cancer is treated.
ORR 71% (naive MTC), 89% (RET-fusion thyroid).
A milestone in how this cancer is treated.